{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T12:53:34Z","timestamp":1793796814585,"version":"4.6.1"},"reference-count":95,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T00:00:00Z","timestamp":1704672000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Janos Bolyai Research"},{"DOI":"10.13039\/501100003825","name":"Hungarian Academy of Sciences","doi-asserted-by":"publisher","award":["BO\/00693\/25\/5"],"award-info":[{"award-number":["BO\/00693\/25\/5"]}],"id":[{"id":"10.13039\/501100003825","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background and Aims<\/jats:title>\n                  <jats:p>Extraintestinal manifestations are frequent in patients with inflammatory bowel disease and have a negative impact on quality of life. Currently, however, there is no evidence available to determine which drug should be recommended for these patients beyond anti-tumour necrosis factor [anti-TNF] treatment. We aimed to analyse the frequency of new extraintestinal manifestations and the behaviour of pre-existing extraintestinal manifestations during advanced therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a systematic search on November 15, 2022, and enrolled randomized controlled trials, cohorts, and case series reporting the occurrence and behaviour of extraintestinal manifestations in patients with inflammatory bowel disease receiving advanced therapy [non-TNF inhibitor biologicals and JAK inhibitors]. Proportions of new, recurring, worsening, and improving extraintestinal manifestations were calculated with 95% confidence intervals [CIs]. The risk of bias was assessed with the QUIPS tool.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Altogether, 61 studies comprising 13,806 patients reported eligible data on extraintestinal manifestations. The overall proportion of new extraintestinal manifestations was 8% [95% CI, 6\u201312%] during advanced therapy. There was no significant difference between the frequency of new extraintestinal manifestations during vedolizumab and ustekinumab therapy [11%, 95% CI, 8\u201315% vs 6%, 95% CI, 3\u201311%, p\u2005=\u20050.166]. The improvement of pre-existing manifestations was comparable between vedolizumab- and ustekinumab-treated patients, except for joint involvement [42%, 95% CI, 32\u201353% vs 54%, 95% CI, 42\u201365%, p\u2005=\u20050.029].<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The proportion of new extraintestinal manifestations was low during advanced therapy. Furthermore, the improvement of pre-existing manifestations was comparable between advanced therapies, except for pre-existing joint manifestations.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjae002","type":"journal-article","created":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T14:27:31Z","timestamp":1704724051000},"page":"851-863","source":"Crossref","is-referenced-by-count":18,"title":["Beyond the Gut: A Systematic Review and Meta-analysis of Advanced Therapies for Inflammatory Bowel Disease-associated Extraintestinal Manifestations"],"prefix":"10.1093","volume":"18","author":[{"given":"\u00c1gnes Eszter","family":"T\u00edm\u00e1r","sequence":"first","affiliation":[{"name":"Heim P\u00e1l National Pediatric Institute , Budapest , Hungary"},{"name":"Centre for Translational Medicine, Semmelweis University , Budapest , Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"P\u00e1rniczky","sequence":"additional","affiliation":[{"name":"Heim P\u00e1l National Pediatric Institute , Budapest , Hungary"},{"name":"Centre for Translational Medicine, Semmelweis University , Budapest , Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinga Anna","family":"Budai","sequence":"additional","affiliation":[{"name":"Centre for Translational Medicine, Semmelweis University , Budapest , Hungary"},{"name":"University Pharmacy Department of Pharmacy Administration, Semmelweis University , Budapest , Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e1rk Viktor","family":"Hern\u00e1df\u0151i","sequence":"additional","affiliation":[{"name":"Centre for Translational Medicine, Semmelweis University , Budapest , Hungary"},{"name":"Bethesda Children\u2019s Hospital , Budapest , Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emese","family":"Kaszn\u00e1r","sequence":"additional","affiliation":[{"name":"Centre for Translational Medicine, Semmelweis University , Budapest , Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e9ter","family":"Varga","sequence":"additional","affiliation":[{"name":"Centre for Translational Medicine, Semmelweis University , Budapest , Hungary"},{"name":"Department of Obstetrics and Gynecology, Semmelweis University , Budapest , Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e9ter","family":"Hegyi","sequence":"additional","affiliation":[{"name":"Centre for Translational Medicine, Semmelweis University , Budapest , Hungary"},{"name":"Institute for Translational Medicine, Medical School, University of P\u00e9cs , P\u00e9cs , Hungary"},{"name":"Institute of Pancreatic Diseases, Semmelweis University , Budapest , Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Szil\u00e1rd","family":"V\u00e1ncsa","sequence":"additional","affiliation":[{"name":"Centre for Translational Medicine, Semmelweis University , Budapest , Hungary"},{"name":"Institute for Translational Medicine, Medical School, University of P\u00e9cs , P\u00e9cs , Hungary"},{"name":"Institute of Pancreatic Diseases, Semmelweis University , Budapest , Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9ka","family":"T\u00f3th","sequence":"additional","affiliation":[{"name":"Centre for Translational Medicine, Semmelweis University , Budapest , Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e1niel S\u00e1ndor","family":"Veres","sequence":"additional","affiliation":[{"name":"Centre for Translational Medicine, Semmelweis University , Budapest , Hungary"},{"name":"Department of Biophysics and Radiation Biology, Semmelweis University , Budapest , Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikl\u00f3s","family":"Garami","sequence":"additional","affiliation":[{"name":"Centre for Translational Medicine, Semmelweis University , Budapest , Hungary"},{"name":"Pediatric Center, Semmelweis University , Budapest , Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katalin Eszter","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"Heim P\u00e1l National Pediatric Institute , Budapest , Hungary"},{"name":"Centre for Translational Medicine, Semmelweis University , Budapest , Hungary"},{"name":"Department of Family Care Methodology, Faculty of Health Sciences, Semmelweis University , Budapest , Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,1,8]]},"reference":[{"key":"2024060402062061000_CIT0001","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11894-019-0698-1","article-title":"Extraintestinal manifestations of inflammatory bowel disease: epidemiology, etiopathogenesis, and management","volume":"21","author":"Garber","year":"2019","journal-title":"Curr Gastroenterol Rep"},{"key":"2024060402062061000_CIT0002","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1053\/j.gastro.2021.07.042","article-title":"Extraintestinal manifestations of inflammatory bowel disease: current concepts, treatment, and implications for disease management","volume":"161","author":"Rogler","year":"2021","journal-title":"Gastroenterology"},{"key":"2024060402062061000_CIT0003","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3109\/07853890903559724","article-title":"Extraintestinal manifestations of inflammatory bowel disease: epidemiology, diagnosis, and management","volume":"42","author":"Larsen","year":"2010","journal-title":"Ann Med"},{"key":"2024060402062061000_CIT0004","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1097\/MIB.0000000000000392","article-title":"Extraintestinal manifestations of inflammatory bowel disease","volume":"21","author":"Vavricka","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"2024060402062061000_CIT0005","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1093\/ecco-jcc\/jjy191","article-title":"The pathogenesis of extraintestinal manifestations: implications for IBD research, diagnosis, and therapy","volume":"13","author":"Hedin","year":"2019","journal-title":"J Crohns Colitis"},{"key":"2024060402062061000_CIT0006","first-page":"e17187","article-title":"Extra-intestinal manifestations of inflammatory bowel disease","volume":"13","author":"Sange","year":"2021","journal-title":"Cureus"},{"key":"2024060402062061000_CIT0007","doi-asserted-by":"crossref","first-page":"45","DOI":"10.5217\/ir.2019.00135","article-title":"Quality of life in inflammatory bowel diseases: it is not all about the bowel","volume":"19","author":"Keller","year":"2021","journal-title":"Intest Res"},{"key":"2024060402062061000_CIT0008","doi-asserted-by":"crossref","first-page":"107","DOI":"10.5217\/ir.2018.00099","article-title":"Health-related quality of life of patients with inflammatory bowel disease in Singapore","volume":"17","author":"Min Ho","year":"2019","journal-title":"Intest Res"},{"key":"2024060402062061000_CIT0009","doi-asserted-by":"crossref","first-page":"517","DOI":"10.3389\/fmed.2020.00517","article-title":"Personalizing treatment in IBD: hype or reality in 2020? Can we predict response to anti-TNF","volume":"7","author":"Atreya","year":"2020","journal-title":"Front Med"},{"key":"2024060402062061000_CIT0010","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","article-title":"ECCO guidelines on therapeutics in Crohn\u2019s disease: medical treatment","volume":"14","author":"Torres","year":"2020","journal-title":"J Crohns Colitis"},{"key":"2024060402062061000_CIT0011","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: medical treatment","volume":"16","author":"Raine","year":"2022","journal-title":"J Crohns Colitis"},{"key":"2024060402062061000_CIT0012","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/ecco-jcc\/jjw168","article-title":"3rd European evidence-based consensus on the diagnosis and management of Crohn\u2019s disease 2016: part 1: diagnosis and medical management","volume":"11","author":"Gomollon","year":"2017","journal-title":"J Crohns Colitis"},{"key":"2024060402062061000_CIT0013","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1093\/ibd\/izy065","article-title":"Extraintestinal manifestations in vedolizumab and anti-TNF-treated patients with inflammatory bowel disease","volume":"24","author":"Dubinsky","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"2024060402062061000_CIT0014","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/ecco-jcc\/jjz119","article-title":"Ustekinumab for Crohn\u2019s disease: results of the ICC registry, a nationwide prospective observational cohort study","volume":"14","author":"Biemans","year":"2020","journal-title":"J Crohns Colitis"},{"key":"2024060402062061000_CIT0015","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/art.40728","article-title":"Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis","volume":"71","author":"Deodhar","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2024060402062061000_CIT0016","doi-asserted-by":"crossref","first-page":"668","DOI":"10.55563\/clinexprheumatol\/e7ayu8","article-title":"Ciccia F JAK\/STAT pathway and nociceptive cytokine signalling in rheumatoid arthritis and psoriatic arthritis","volume":"39","author":"Crispino","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"2024060402062061000_CIT0017","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s40257-020-00578-0","article-title":"Use of IL-23 inhibitors for the treatment of plaque psoriasis and psoriatic arthritis: a comprehensive review","volume":"22","author":"Yang","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"2024060402062061000_CIT0018","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1093\/ecco-jcc\/jjaa260","article-title":"Ustekinumab for extra-intestinal manifestations of inflammatory bowel disease: a systematic literature review","volume":"15","author":"Guillo","year":"2021","journal-title":"J Crohns Colitis"},{"key":"2024060402062061000_CIT0019","doi-asserted-by":"crossref","first-page":"105906","DOI":"10.1016\/j.ijsu.2021.105906","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"88","author":"Page","year":"2021","journal-title":"Int J Surg"},{"key":"2024060402062061000_CIT0020","author":"Higgins"},{"key":"2024060402062061000_CIT0021","author":"Haddaway"},{"key":"2024060402062061000_CIT0022","doi-asserted-by":"crossref","first-page":"280","DOI":"10.7326\/0003-4819-158-4-201302190-00009","article-title":"Assessing bias in studies of prognostic factors","volume":"158","author":"Hayden","year":"2013","journal-title":"Ann Intern Med"},{"key":"2024060402062061000_CIT0023","volume-title":"Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach","author":"Sch\u00fcnemann","year":"2013"},{"key":"2024060402062061000_CIT0024","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"2024060402062061000_CIT0025","volume-title":"Doing Meta-Analysis With R: A Hands-on Guide.","author":"Harrer","year":"2022","edition":"1"},{"key":"2024060402062061000_CIT0026","article-title":"A general","author":"Viechtbauer","year":"2021"},{"key":"2024060402062061000_CIT0027","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1001\/jama.295.6.676","article-title":"Comparison of two methods to detect publication bias in meta-analysis","volume":"295","author":"Peters","year":"2006","journal-title":"JAMA"},{"key":"2024060402062061000_CIT0028","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-21416-0","volume-title":"Meta-Analysis with R.","author":"Schwarzer","year":"2015"},{"key":"2024060402062061000_CIT0029","author":"Harrer M, Cuijpers","year":"2019"},{"key":"2024060402062061000_CIT0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting meta-analyses in R with the metafor package","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J Stat Softw"},{"key":"2024060402062061000_CIT0031","doi-asserted-by":"crossref","first-page":"S-701","DOI":"10.1016\/S0016-5085(21)02382-9","article-title":"Effectiveness of ustekinumab for management of extraintestinal manifestations of Crohn\u2019s disease","volume":"160","author":"Aboubakr","year":"2021","journal-title":"Gastroenterology"},{"key":"2024060402062061000_CIT0032","article-title":"Real-world safety and efficacy of ustekinumab","author":"Anjur"},{"key":"2024060402062061000_CIT0033","first-page":"S867","article-title":"Proceedings of the World Congress of Gastroenterology","volume":"30","author":"Bacaks\u0131z","year":"2020","journal-title":"Turk J Gastroenterol"},{"key":"2024060402062061000_CIT0034","doi-asserted-by":"crossref","first-page":"S399","DOI":"10.1093\/ecco-jcc\/jjy222.695","article-title":"Effectiveness and safety of ustekinumab for induction of remission in patients with Crohn\u2019s disease: a multi-centre Israeli study","volume":"13","author":"Bar-Gil Shitrit","year":"2019","journal-title":"J Crohns Colitis"},{"key":"2024060402062061000_CIT0035","first-page":"A753","article-title":"Efficacy of vedolizumab induction therapy in patients with severe, therapeutic resistant inflammatory bowel disease UEG week 2017 poster presentations","volume":"5","author":"Bor","year":"2017","journal-title":"United Eur Gastroenterol J"},{"key":"2024060402062061000_CIT0036","doi-asserted-by":"crossref","first-page":"i375","DOI":"10.1093\/ecco-jcc\/jjab232.500","article-title":"P373 Real world evidence of tofacinitib in ulcerative colitis: short and long-term effectiveness, impact of extraintestinal manifestations and immunomediated diseases and safety","volume":"16","author":"Chaparro","year":"2022","journal-title":"J Crohns Colitis"},{"key":"2024060402062061000_CIT0037","doi-asserted-by":"crossref","first-page":"S-865","DOI":"10.1016\/S0016-5085(15)32933-4","article-title":"Skin and joint side effects in a subpopulation of anti-TNF experienced IBD patients, who respond to a treatment with vedolizumab, a humanized A4b7 integrin antibody","volume":"148","author":"Drvarov","year":"2015","journal-title":"Gastroenterology"},{"key":"2024060402062061000_CIT0038","doi-asserted-by":"crossref","first-page":"A177.1","DOI":"10.1136\/ejhpharm-2020-eahpconf.377","article-title":"Effectiveness and safety of ustekinumab in clinical practice for Crohn\u2019s disease","volume-title":"Section 5: Patient Safety and Quality assurance","author":"Fages","year":"2020"},{"key":"2024060402062061000_CIT0039","doi-asserted-by":"crossref","first-page":"S308\u20139","DOI":"10.1093\/ecco-jcc\/jjab076.401","article-title":"Influence of vedolizumab on extraintestinal manifestations in inflammatory bowel disease: a nationwide multicenter study of the GETECCU Eneida registry","volume":"15","author":"P\u00e9rez Galindo","year":"2021","journal-title":"J Crohns Colitis"},{"key":"2024060402062061000_CIT0040","doi-asserted-by":"crossref","first-page":"S-844","DOI":"10.1016\/S0016-5085(18)32863-4","article-title":"Joint pain in patients with inflammatory bowel disease treated with vedolizumab: an extra-intestinal manifestation or a side effect of a gut-specific therapy","volume":"154","author":"Gold","year":"2018","journal-title":"Gastroenterology"},{"key":"2024060402062061000_CIT0041","doi-asserted-by":"crossref","first-page":"S387","DOI":"10.1093\/ecco-jcc\/jjab076.494","article-title":"Concomitant azathioprine prevents new-onset arthralgia after initiation of vedolizumab: A retrospective cohort study","volume":"15","author":"Kokkotis","year":"2021","journal-title":"J Crohns Colitis"},{"key":"2024060402062061000_CIT0042","doi-asserted-by":"crossref","first-page":"S412","DOI":"10.1093\/ecco-jcc\/jjab076.530","article-title":"A retrospective analysis of the efficacy of vedolizumab on extra-intestinal manifestations in patients with inflammatory bowel disease across five European countries","volume":"15","author":"Kopylov","year":"2021","journal-title":"J Crohns Colitis"},{"key":"2024060402062061000_CIT0043","first-page":"S707","article-title":"Efficacy, persistence and optimization of ustekinumab in ulcerative colitis: clinical data UEG Week 2022 poster presentations","volume":"10","author":"Latras Cort\u00e9s","year":"2022","journal-title":"United Eur Gastroenterol J"},{"key":"2024060402062061000_CIT0044","doi-asserted-by":"crossref","first-page":"S-450-S-451","DOI":"10.1016\/S0016-5085(20)31809-6","article-title":"Colitis patients with PSC may gain additional benefit from the use of tofacitinib","volume":"158","author":"Lewis","year":"2020","journal-title":"Gastroenterology"},{"key":"2024060402062061000_CIT0045","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.dld.2018.02.013","article-title":"The real-world effectiveness of vedolizumab on intestinal and articular outcomes in inflammatory bowel diseases","volume":"50","author":"Macaluso","year":"2018","journal-title":"Dig Liver Dis"},{"key":"2024060402062061000_CIT0046","first-page":"S476","article-title":"Effectiveness of ustekinumab on Crohn\u2019s disease associated spondyloarthropathy UEG week 2020 poster presentations","volume":"8","author":"Macaluso","year":"2020","journal-title":"United Eur Gastroenterol J"},{"key":"2024060402062061000_CIT0047","doi-asserted-by":"crossref","first-page":"S317","DOI":"10.14309\/00000434-201610001-00705","article-title":"Vedolizumab in inflammatory bowel disease: a retrospective review of clinical efficacy, extra-intestinal manifestations and adverse reactions","volume":"111","author":"Patel","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"2024060402062061000_CIT0048","doi-asserted-by":"crossref","first-page":"S057","DOI":"10.1093\/ecco-jcc\/jjy222.084","article-title":"Effect of upadacitinib on extra-intestinal manifestations in patients with moderate to severe Crohn\u2019s disease: data from the CELEST study","volume":"13","author":"Peyrin-Biroulet","year":"2019","journal-title":"J Crohns Colitis"},{"key":"2024060402062061000_CIT0049","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1093\/ibd\/zaa010.006","article-title":"Real-world comparison of arthralgias with infliximab vs vedolizumab in the treatment of bio-naive inflammatory bowel disease","volume":"26","author":"Ritter","year":"2020","journal-title":"Inflamm Bowel Dis"},{"key":"2024060402062061000_CIT0050","doi-asserted-by":"crossref","first-page":"S1482","DOI":"10.14309\/00000434-201710001-02733","article-title":"Ustekinumab for moderate to severe Crohn\u2019s disease and its extraintestinal manifestations","volume":"112","author":"Singh","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"2024060402062061000_CIT0051","first-page":"450","article-title":"Utility of ustekinumab in articular pathology associated with Crohn\u2019s disease UEG week 2020 poster presentations","volume":"8","author":"Su\u00e1rez Ferrer","year":"2020","journal-title":"United Eur Gastroenterol J"},{"key":"2024060402062061000_CIT0052","first-page":"751","article-title":"The association between vedolizumab and the development of new-onset features of spondyloarthritis in patients with inflammatory bowel disease: a pilot study","volume-title":"JRheumatol","author":"Tauqir","year":"2022"},{"key":"2024060402062061000_CIT0053","doi-asserted-by":"crossref","first-page":"S302","DOI":"10.1093\/ecco-jcc\/jjab076.391","article-title":"The impact of vedolizumab and ustekinumab on arthropathy and arthralgia in IBD patients: a real-life multicentric cohort study","volume":"15","author":"Truyens","year":"2021","journal-title":"J Crohns Colitis"},{"key":"2024060402062061000_CIT0054","doi-asserted-by":"crossref","first-page":"S402","DOI":"10.1016\/S0016-5085(17)31580-9","article-title":"Efficacy of vedolizumab in reducing biliary inflammation in primary sclerosing cholangitis (PSC) in individuals with inflammatory bowel disease","volume":"152","author":"Tse","year":"2017","journal-title":"Gastroenterology"},{"key":"2024060402062061000_CIT0055","doi-asserted-by":"crossref","first-page":"S441","DOI":"10.1093\/ecco-jcc\/jjab076.566","article-title":"Serum vedolizumab trough levels are associated with remission rate but not with extra-intestinal manifestations in IBD patients","volume":"15","author":"Tzadok","year":"2021","journal-title":"J Crohns Colitis"},{"key":"2024060402062061000_CIT0056","doi-asserted-by":"crossref","first-page":"S1186","DOI":"10.1016\/S0016-5085(17)33957-4","article-title":"Clinical and translational outcomes in patients with primary sclerosing cholangitis and inflammatory bowel disease receiving vedolizumab","volume":"152","author":"Williamson","year":"2017","journal-title":"Gastroenterology"},{"key":"2024060402062061000_CIT0057","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1111\/apt.13594","article-title":"Vedolizumab induction therapy for inflammatory bowel disease in clinical practice - a nationwide consecutive German cohort study","volume":"43","author":"Baumgart","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"2024060402062061000_CIT0058","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/apt.17305","article-title":"Real-world comparison of effectiveness between tofacitinib and vedolizumab in patients with ulcerative colitis exposed to at least one anti-TNF agent","volume":"57","author":"Buisson","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"2024060402062061000_CIT0059","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1093\/ibd\/izy127","article-title":"The association between arthralgia and vedolizumab using natural language processing","volume":"24","author":"Cai","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"2024060402062061000_CIT0060","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1093\/ecco-jcc\/jjz088","article-title":"Vedolizumab therapy is ineffective for primary sclerosing cholangitis in patients with inflammatory bowel disease: a GETAID multicentre cohort study","volume":"13","author":"Caron","year":"2019","journal-title":"J Crohns Colitis"},{"key":"2024060402062061000_CIT0061","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1007\/s10620-022-07716-0","article-title":"Endo-histologic normalization is achievable with tofacitinib and is associated with improved clinical outcomes","volume":"68","author":"Cohen","year":"2023","journal-title":"Dig Dis Sci"},{"key":"2024060402062061000_CIT0062","doi-asserted-by":"crossref","first-page":"i036","DOI":"10.1093\/ecco-jcc\/jjab232.032","article-title":"Effect of upadacitinib (UPA) treatment on extraintestinal manifestations (EIMs) in patients with moderate-to-severe ulcerative colitis (UC): results from the UPA Phase 3 programme","volume":"16","author":"Colombel","year":"2022","journal-title":"J Crohns Colitis"},{"key":"2024060402062061000_CIT0063","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1093\/ecco-jcc\/jjac058","article-title":"The impact of vedolizumab and ustekinumab on articular extra-intestinal manifestations in inflammatory bowel disease patients: a real-life multicentre cohort study","volume":"16","author":"De Galan","year":"2022","journal-title":"J Crohns Colitis"},{"key":"2024060402062061000_CIT0064","doi-asserted-by":"crossref","first-page":"5809","DOI":"10.1093\/rheumatology\/keab135","article-title":"Prevalence and real-world management of vedolizumab-associated enthesitis in successfully treated IBD patients","volume":"60","author":"Ruscio","year":"2021","journal-title":"Rheumatology (Oxford, England)"},{"key":"2024060402062061000_CIT0065","first-page":"75","article-title":"Vedolizumab-induced de novo extraintestinal manifestations","volume":"16","author":"Diaz","year":"2020","journal-title":"Gastroenterol Hepatol"},{"key":"2024060402062061000_CIT0066","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1093\/rheumatology\/keaa107","article-title":"Articular manifestations in patients with inflammatory bowel disease treated with vedolizumab","volume":"59","author":"Dupr\u00e9","year":"2020","journal-title":"Rheumatology (Oxford, England)"},{"key":"2024060402062061000_CIT0067","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1093\/ibd\/izz057","article-title":"Comparative efficacy of vedolizumab and adalimumab in ulcerative colitis patients previously treated with infliximab","volume":"25","author":"Favale","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"2024060402062061000_CIT0068","doi-asserted-by":"crossref","first-page":"933357","DOI":"10.3389\/fmed.2022.933357","article-title":"The impact of biologic therapies on extra-intestinal manifestations in inflammatory bowel disease: a multicenter study","volume":"9","author":"Ferretti","year":"2022","journal-title":"Front Med"},{"key":"2024060402062061000_CIT0069","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1111\/apt.15958","article-title":"Real-world long-term effectiveness of ustekinumab in Crohn\u2019s disease: results from the ENEIDA registry","volume":"52","author":"Iborra","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"2024060402062061000_CIT0070","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.dld.2022.09.009","article-title":"Ustekinumab and vedolizumab for extraintestinal manifestations in inflammatory bowel disease - a retrospective study","volume":"55","author":"Livne-Margolin","year":"2023","journal-title":"Dig Liver Dis"},{"key":"2024060402062061000_CIT0071","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.cgh.2019.05.013","article-title":"Effects of vedolizumab in patients with primary sclerosing cholangitis and inflammatory bowel diseases","volume":"18","author":"Lynch","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2024060402062061000_CIT0072","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.jbspin.2019.01.008","article-title":"Vedolizumab has no efficacy on articular manifestations in patients with spondyloarthritis associated with inflammatory bowel disease","volume":"86","author":"Paccou","year":"2019","journal-title":"Joint Bone Spine"},{"key":"2024060402062061000_CIT0073","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1093\/ibd\/izaa293","article-title":"The impact of vedolizumab on pre-existing extraintestinal manifestations of inflammatory bowel disease: a multicenter study","volume":"27","author":"Ramos","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"2024060402062061000_CIT0074","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1007\/s10620-019-05982-z","article-title":"Low rate of drug discontinuation, frequent need for dose adjustment, and no association with development of new arthralgia in patients treated with vedolizumab: results from a tertiary referral IBD center","volume":"65","author":"Reinglas","year":"2020","journal-title":"Dig Dis Sci"},{"key":"2024060402062061000_CIT0075","doi-asserted-by":"crossref","first-page":"175628482110724","DOI":"10.1177\/17562848211072412","article-title":"Effectiveness of ustekinumab in patients with refractory Crohn\u2019s disease: a multicentre real-life study in Italy","volume":"15","author":"Scribano","year":"2022","journal-title":"Therap Adv Gastroenterol"},{"key":"2024060402062061000_CIT0076","first-page":"izac149","article-title":"Clinical, endoscopic, and radiological effectiveness of ustekinumab in bio-na\u00efve versus bio-experienced patients with Crohn\u2019s disease: real-world experience from a large Canadian center","volume":"29","author":"Sedano","year":"2022","journal-title":"Inflamm Bowel Dis"},{"key":"2024060402062061000_CIT0077","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1097\/MIB.0000000000000561","article-title":"Efficacy of vedolizumab as induction therapy in refractory IBD patients: a multicenter cohort","volume":"21","author":"Shelton","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"2024060402062061000_CIT0078","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1111\/apt.13813","article-title":"Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study","volume":"44","author":"Stallmach","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"2024060402062061000_CIT0079","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/apt.14419","article-title":"Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort","volume":"47","author":"Tadbiri","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"2024060402062061000_CIT0080","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s10620-022-07582-w","article-title":"Upadacitinib is safe and effective for Crohn\u2019s disease: real-world data from a tertiary center","volume":"68","author":"Traboulsi","year":"2023","journal-title":"Dig Dis Sci"},{"key":"2024060402062061000_CIT0081","doi-asserted-by":"crossref","first-page":"175628482093653","DOI":"10.1177\/1756284820936536","article-title":"Good efficacy and safety of vedolizumab in Crohn\u2019s disease and ulcerative colitis in a real-world scenario","volume":"13","author":"Zingone","year":"2020","journal-title":"Therap Adv Gastroenterol"},{"key":"2024060402062061000_CIT0082","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1002\/cpt.1712","article-title":"Vedolizumab for inflammatory bowel disease: two-year results of the initiative on Crohn and colitis (ICC) registry, a nationwide prospective observational cohort study: ICC registry \u2013 vedolizumab","volume":"107","author":"Biemans","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"2024060402062061000_CIT0083","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1093\/ibd\/izx067","article-title":"Vedolizumab as induction and maintenance for inflammatory bowel disease: 12-month effectiveness and safety","volume":"24","author":"Christensen","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"2024060402062061000_CIT0084","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1097\/MIB.0000000000000918","article-title":"Vedolizumab therapy in severe pediatric inflammatory bowel disease","volume":"22","author":"Conrad","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"2024060402062061000_CIT0085","doi-asserted-by":"crossref","first-page":"105","DOI":"10.21518\/2079-701X-2022-16-15-105-116","article-title":"Efficacy and safety of ustekinumab therapy in patients with Crohn\u2019s disease Real clinical practice","volume":"15","author":"Knyazev","year":"2022","journal-title":"Meditsinskiy Sov Med Counc"},{"key":"2024060402062061000_CIT0086","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1136\/annrheumdis-2016-211011","article-title":"Clinical benefit of vedolizumab on articular manifestations in patients with active spondyloarthritis associated with inflammatory bowel disease","volume":"76","author":"Orlando","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2024060402062061000_CIT0087","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1093\/ecco-jcc\/jjy125","article-title":"Incidence of arthritis\/arthralgia in inflammatory bowel disease with long-term vedolizumab treatment: post hoc analyses of the GEMINI trials","volume":"13","author":"Feagan","year":"2019","journal-title":"J Crohns Colitis"},{"key":"2024060402062061000_CIT0088","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/ueg2.12094","article-title":"The impact of ustekinumab on extraintestinal manifestations of Crohn\u2019s disease: a post hoc analysis of the UNITI studies","volume":"9","author":"Narula","year":"2021","journal-title":"United Eur Gastroenterol J"},{"key":"2024060402062061000_CIT0089","doi-asserted-by":"crossref","first-page":"175628482110057","DOI":"10.1177\/17562848211005708","article-title":"Extraintestinal manifestations at baseline, and the effect of tofacitinib, in patients with moderate to severe ulcerative colitis","volume":"14","author":"Rubin","year":"2021","journal-title":"Therap Adv Gastroenterol"},{"key":"2024060402062061000_CIT0090","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1093\/ecco-jcc\/jjz095","article-title":"Vedolizumab treatment in extra-intestinal manifestations in inflammatory bowel disease: a systematic review","volume":"13","author":"Chateau","year":"2019","journal-title":"J Crohns Colitis"},{"key":"2024060402062061000_CIT0091","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1177\/2050640620958902","article-title":"Clinical management of the most common extra-intestinal manifestations in patients with inflammatory bowel disease focused on the joints, skin and eyes","volume":"8","author":"Jansen","year":"2020","journal-title":"United Eur Gastroenterol J"},{"key":"2024060402062061000_CIT0092","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/14712598.2020.1689953","article-title":"Choosing the most appropriate biologic therapy for Crohn\u2019s disease according to \u2011concomitant extra-intestinal manifestations, comorbidities, or physiologic conditions","volume":"20","author":"Romano","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"2024060402062061000_CIT0093","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1093\/ecco-jcc\/jjz102","article-title":"Vedolizumab in IBD\/PSC: a case for careful vigilance","volume":"13","author":"Jones","year":"2019","journal-title":"J Crohns Colitis"},{"key":"2024060402062061000_CIT0094","doi-asserted-by":"crossref","first-page":"S1542356523000733","DOI":"10.1016\/j.cgh.2023.01.014","article-title":"Evaluation of tofacitinib in primary sclerosing cholangitis and associated colitis: a multicenter, retrospective study","volume":"21","author":"Schregel","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2024060402062061000_CIT0095","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/ecco-jcc\/jjv213","article-title":"The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease","volume":"10","author":"Harbord","year":"2016","journal-title":"J Crohns Colitis"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjae002\/56346182\/jjae002.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/18\/6\/851\/58069440\/jjae002.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/18\/6\/851\/58069440\/jjae002.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T02:07:53Z","timestamp":1717466873000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/18\/6\/851\/7512824"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,8]]},"references-count":95,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,1,8]]},"published-print":{"date-parts":[[2024,6,3]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjae002","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,6,1]]},"published":{"date-parts":[[2024,1,8]]}}}